Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: Results from a European noninterventional registry study.
CONCLUSION: The study provided valuable information on LGS and its management, and evidence that rufinamide has a consistent and generally favorable safety/tolerability profile when used in routine clinical practice. CLINICALTRIALS.
GOV IDENTIFIER: NCT01991041.
PMID: 28927712 [PubMed - as supplied by publisher]
Source: Epilepsy and Behaviour - Category: Neurology Authors: Nikanorova M, Brandt C, Auvin S, McMurray R Tags: Epilepsy Behav Source Type: research